This post has expired! It was posted more than 90 days ago.
<- Back

154311 - HIV: Exploring new coformulated options

  • : Online

Combination antiretroviral therapy (ARV) can reduce HIV-associated morbidity, prolong survival and prevent HIV transmission. A key goal in reducing the burden of HIV/AIDS, therefore, requires bringing HIV treatment to all those who need it. The aim of this activity is to help S100 Prescribers and GPs review the pharmacokinetic profiles of HIV drug regimens and use this information to assess the risks and benefits of various polydrug regimens given patients' comorbidities and HIV status.

Relevance to General Practice

The lifelong, uninterrupted ARV therapy needed for this prolonged virologic suppression means, however, that patients may be exposed to ARV drugs for decades. Ageing populations with HIV have also been shown to experience more age-related comorbidities than their HIV-uninfected peers. Maximising the long-term tolerability of ARV regimens while maintaining strong clinical efficacy is therefore a high priority in the management of individuals with HIV. GPs may be the first contact point for people living with HIV (PLWHIV) and play a vital role in the counselling PLWHIV in treatment regimens and managing comorbidities.

Learning outcomes
  • Review HIV comorbidities, and risk factors for comorbidities
  • Outline the recommended regimens that can minimise comorbidities while optimising patient safety
  • Discuss findings from recent studies regarding the efficacy and tolerability of B/F/TAF
  • Identify optimal treatment choices for individual patients, considering older and newer treatment regimens and current guidelines
  • Delivery
    154311 - HIV: Exploring new coformulated options
    Provider Type
    Education Provider
    1 hour
    Start Date
    End Date
    CPD Points
    1 hour
    Contact Phone
    Log in into view this field.